Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Friday, November 1, 2019

Investor Ideas adds New #Stocks in Cannabis (CSE: $MXT.C) (CSE: $PRMO.C), Biotech (Nasdaq: $IPHA, $VIR, $BNRX, $FREQ) and Tech (CSE: $AMPD.C) (CSE: $TKR.C)

Investor Ideas adds New #Stocks in Cannabis (CSE: $MXT.C) (CSE: $PRMO.C), Biotech (Nasdaq: $IPHA, $VIR, $BNRX, $FREQ) and Tech (CSE: $AMPD.C) (CSE: $TKR.C)




Point Roberts WA, Delta BC, November 1, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in cannabis, biotech and tech.


This week’s new cannabis companies are both CSE-listed and are involved in COextraction and financing for the cannabis industry, respectively.

The latest biotech/life sciences companies are all October Nasdaq IPOs.

The newest tech companies are both CSE-listed and are involved in cloud computing and IoT & AI, respectively.

New Cannabis Companies:
MedXtractor Corp. (CSE:MXT) is a Calgary-based company that manufactures patented, proprietary small-scale carbon dioxide-based extractors that are used to extract essential oils and compounds from a variety of botanical materials. At present, the Corporation targets the "Craft" cannabis grower. Craft growers are those whose crop is up to 800 indoor-sized plants per crop cycle. In management's opinion, CO2 Extractors represent the state-of-the-art for high-potency, high-purity oils, one of the fastest growing segments of the overall cannabis market. Cannabis oils can be extracted from flowers (bud), trim (leaves) and/or post-pressed rosin "chips" (leftovers from hydraulic press extraction). The ongoing worldwide legalization of cannabis is underpinning the rapidly growing demand for cannabis products with major growth seen in oils due to their utility as feedstock for various ingestion methods. The Corporation owns the patents on its CO2 Extractors.

Primo Nutraceuticals Inc. (CSE:PRMO) formerly Bougainville Ventures Inc - provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. We offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Cultivators lease these facilities and pay affordable fee-based management costs to accelerate market entry and scalability. The first 10,000 square feet of greenhouse space in Oroville, Washington has been completed and is ready for occupancy. Our facilities remove financial barriers for cannabis cultivators as traditional funding is limited due to United States federal laws and current lending practices.

New Biotech Companies:
INNATE PHARMA SA (NasdaqGS: IPHA) is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate Pharma has been a pioneer in the understanding of NK cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

VIR BIOTECHNOLOGY, INC(NasdaqGS:VIR) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis

BIONTECH SE (NasdaqGS:BNTX) was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach.

FREQUENCY THERAPEUTICS, INC(NasdaqGS:FREQ) is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. In a FX-322 Phase 1/2 study, the company observed statistically significant and clinically meaningful improvement in key measures of hearing function in patients with sensorineural hearing loss. The company is evaluating additional diseases where its PCA approach could create functional tissue, including a development program in multiple sclerosis. Headquartered in Woburn, Mass., Frequency has a development and commercialization agreement with Astellas Pharma Inc. for FX-322, for which it retains U.S. rights, as well as additional collaboration agreements with academic and nonprofit research organizations including The Scripps Research Institute, Massachusetts Eye and Ear, and the Massachusetts Institute of Technology.

VIELA BIO, INC. (NasdaqGS:VIE) headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases.

APREA THERAPEUTICS, INC. (NasdaqGS:APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate  mutant tumor suppressor protein, p53. The Company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Neovasc, Inc. (TSX: NVCN.TONASDAQ: NVCN) is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. 

New Tech Companies:
AMPD Ventures Inc. (CSE:AMPD) specializes in providing high-performance cloud and compute solutions for low-latency applications including video games and eSports, digital animation and visual effects, and big data collection, analysis and visualization.

Tracker Ventures Corp. (CSE:TKR) – formerly TrackLoop - is an analytics software company that is leveraging digital asset technology to transform and modernize multiple industries. TrackLoop is taking a diversified approach to the analytics and technology space, delivering practical solutions in the finance, logistics, cannabis, and pharmaceutical industries. The Company’s turnkey real-time tracking solutions offer the very latest in IoT and AI, providing valuable data and business intelligence to some of the world’s leading brands.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas
Download our Mobile App for iPhone and Android  

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411
























No comments:

Post a Comment